share_log

和鉑醫藥-B：內幕消息 - 有關開發巴托利單抗(HBM9161)的進展

HBM HOLDINGS-B: INSIDE INFORMATION - UPDATE ON THE DEVELOPMENT FOR BATOCLIMAB (HBM9161)

Hong Kong Stock Exchange ·  Jun 27 06:11
Summary by Futu AI
和鉑醫藥-B於2024年6月26日向中國國家藥品監督管理局（NMPA）再次提交了巴托利單抗（HBM9161）的生物製品許可申請（BLA）。巴托利單抗是一種全人源單克隆抗體，專門結合及抑制新生兒FcRn，有望成為治療大中華區多種自身免疫性疾病的新療法。公司提醒股東及潛在投資者，並無法保證最終能成功營銷此藥物，並應審慎行事。公告中亦包含前瞻性陳述，但公司不保證定期更新這些陳述，並指出實際結果可能因多種因素而與預期存在差異。
和鉑醫藥-B於2024年6月26日向中國國家藥品監督管理局（NMPA）再次提交了巴托利單抗（HBM9161）的生物製品許可申請（BLA）。巴托利單抗是一種全人源單克隆抗體，專門結合及抑制新生兒FcRn，有望成為治療大中華區多種自身免疫性疾病的新療法。公司提醒股東及潛在投資者，並無法保證最終能成功營銷此藥物，並應審慎行事。公告中亦包含前瞻性陳述，但公司不保證定期更新這些陳述，並指出實際結果可能因多種因素而與預期存在差異。
On June 26, 2024, BeiGene Medicine B submitted a biological product license application (BLA) for batolimumab (HBM9161) to the National Medical Products Administration (NMPA) of China again. Batolimumab is a fully human monoclonal antibody that specifically binds and inhibits neonatal FcRn, which is expected to become a new treatment for a variety of autoimmune diseases in the Greater China region. The company reminds shareholders and potential investors that it is not guaranteed that the drug will be successfully marketed and should proceed with caution. The announcement also contains forward-looking statements, but the company does not guarantee to update these statements regularly and points out that actual results may differ from expectations for various reasons.
On June 26, 2024, BeiGene Medicine B submitted a biological product license application (BLA) for batolimumab (HBM9161) to the National Medical Products Administration (NMPA) of China again. Batolimumab is a fully human monoclonal antibody that specifically binds and inhibits neonatal FcRn, which is expected to become a new treatment for a variety of autoimmune diseases in the Greater China region. The company reminds shareholders and potential investors that it is not guaranteed that the drug will be successfully marketed and should proceed with caution. The announcement also contains forward-looking statements, but the company does not guarantee to update these statements regularly and points out that actual results may differ from expectations for various reasons.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.